A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Apr 11, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called JNJ-77242113 for people with moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. The main goal of the study is to see how effective JNJ-77242113 is compared to a placebo (which is an inactive treatment) and another medication called ustekinumab. If you or a loved one have been diagnosed with plaque psoriasis and have a significant amount of skin affected, you might be eligible to participate.

To qualify for the study, participants need to have a certain level of severity in their psoriasis, meaning at least 10% of their body surface area is affected. They should not have other forms of psoriasis or certain health issues that could interfere with the study. The trial is not yet recruiting participants, but if you join, you can expect close monitoring and care while receiving either the new treatment or one of the comparisons. This trial aims to gather important information to help improve treatments for plaque psoriasis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
• • Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
• • Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
• • Total investigator global assessment (IGA) \>=3 at screening and baseline
• • Candidate for phototherapy or systemic treatment for plaque psoriasis
• Exclusion Criteria:
• • Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
• • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
• • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
• • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
• • Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)